Why Is ZYMEWORKS INC (ZYME) Stock Down Today?

Zymeworks Inc (ZYME) shares fell 7.60% to $29.07, a move that occurred despite recent positive analyst revisions and strong quarterly earnings. The primary driver of the decline appears to be a technical pullback from recent highs, as the stock had previously rallied over the last eight sessions.

What Happened

Zymeworks reported third-quarter 2026 financial results, posting earnings per share of $2.28, which exceeded the consensus estimate of $2.19. The company also raised its full-year guidance following the announcement. In response to the strong performance, several investment banks adjusted their outlooks. Citigroup maintained its Buy rating and raised its price target to $44.00 from $39.00. TD Cowen also maintained a Buy rating, lifting its target to $39.00. Additionally, Truist Securities and HC Wainwright & Co. maintained Buy ratings, with price targets raised to $36.00 and $56.00, respectively. Despite these upgrades, the stock traded lower in the session, suggesting that the positive news may have already been priced in or that investors are taking profits after a recent run-up.

What The Data Shows

The stock’s recent trajectory shows a sharp reversal from its immediate past performance. Over the last eight sessions, the shares had moved up 10.0%, rising from $28.61 to $31.46 before the current decline. The company currently has a market capitalization of $2.2 billion and a P/E ratio of 56.6. Trailing twelve-month revenue grew 97.8%, and the net margin stands at 16.3%. The stock’s beta is 1.30, indicating higher volatility than the broader market. The 52-week range is $16.57 to $31.97. Notably, the stock printed 11 fresh 52-week lows on November 11, 2026, highlighting recent volatility in the lower part of its range. On the insider front, Adam Schayowitz, Executive Vice President and Head of R&D, sold shares totaling $358,000 on October 9, 2026. There have been no insider buys in the last 90 days.

What To Watch

Investors will monitor how the stock reacts to the recent price target increases from major banks. The gap between the current price of $29.07 and the highest new target of $56.00 suggests significant potential upside if the market continues to digest the raised guidance.